108 Views

Luxury travel deals site Secret Escapes grabs $60 mln

London-based Secret Escapes, a luxury travel deals site, has raised $60 million in Series C funding. Google Ventures and Octopus Investments led the round with participation from return backers Index Ventures and Atlas Venture. Torch Partners was the advisor on the transaction.

RaNA Therapeutics snaps up $55 mln

Cambridge, Massachusetts-based RaNA Therapeutics, a RNA-focused drug developer, has closed $55 million in Series B funding. MRL Ventures and the Baupost Group LLC led the round with participation from other investors that included Rock Springs Capital Management, Brookside Capital, Leerink Partners LLC, Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One. In addition to the funding, Dr. Joshua Resnick, president of MRL Ventures, has been added to RaNA’s board of directors.

Canadian advocate marketing company Influitive snags $30.5 mln

Toronto-based advocate marketing company Influitive has raised $30.5 million in Series B funding. Georgian Partners led the round with participation from other investors that included OurCrowd, Atlas Venture, Docomo Capital, BDC Capital IT Venture Fund, Hummer Winblad Venture Partners, Illuminate Ventures, Resolute Ventures, Relay Ventures and First Round Capital. In conjunction with the funding, Simon Chong of Georgian Partners has been added to Influitive’s board of directors.

New Leaf Venture Partners leads Series B round for Unum Therapeutics

Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum’s board of directors.

148 Views

Spero Therapeutics fetches $30 mln Series A

Cambridge, Massachusetts-based Spero Therapeutics LLC, a biopharmaceutical company that focuses on treating bacterial infections, has raised $30 million in Series A funding. Lundbeckfond Ventures led the round with participation from other investors that included Merck Research Ventures, The Kraft Group, Atlas Venture, SR One and Partners Innovation Fund. In conjunction with the funding, Lundbeckfond Ventures’s Casper Breum and Merck’s Dr. Josh Resnick have been added to Spero’s board.

199 Views

PillPack grabs $50 mln in CRV-led round

PillPack, a pharmacy that simplifies medication management, has closed $50 million in funding. CRV led the round with participation from Accel Partners, Atlas Venture, Menlo Ventures and Sherpa Ventures. In addition to the funding, George Zachary, a partner at CRV, has been appointed to PillPack’s board.

VC-backed JenaValve appoints new CEO

Munich, Germany and Irvine, California-based JenaValve Technology, a provider of transcatheter aortic valve implantation systems that treat aortic valve disease, has named Dr. Victoria E. Carr-Brendel as CEO. The appointment is effective immediately. Previously, Dr. Carr-Bendel served as general manager of Boston Scientific’s Bayer Interventional business. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.

VC-backed Intellia Therapeutics appoints chief financial and strategy officer

Intellia Therapeutics, a developer of therapeutic products for gene editing and repair, has named Dr. Sapna Srivastava as chief financial and strategy officer. She is a former senior analyst and biotechnology group team leader at Goldman Sachs. Intellia Therapeutics is backed by Atlas Venture and Novartis Institutes for Biomedical Research.

131 Views

Programmatic TV startup Clypd pulls in $19.4 mln

Boston-based programmatic TV startup Clypd has raised $19.4 million in Series B funding. RTL Group led the round with participation from Atlas Venture, Data Point Capital, Duke University, TiVo Inc, Transmedia Capital and Western Technology Investment.

103 Views

Nimbus Therapeutics pulls in $43 mln

Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company’s previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.

111 Views

Sqrrl grabs $7 mln in Rally Ventures-led round

Cambridge, Massachusetts-based big data analytics company Sqrrl has raised $7 million in Series B funding. Rally Ventures led the round with participation from previous backers Atlas Venture and Matrix Partners.

114 Views

Art tech startup Cuseum snags $1.2 mln seed

Boston-based art tech startup Cuseum has raised $1.2 million in seed funding. The investors included Foundry Group’s FG Angels, Atlas Venture’s Boston Syndicates, Seavest Capital Partners, Drummond Road Capital and New Gen Partners.

115 Views

The Medicines Company buys Annovation Biopharma

The Medicines Company said Wednesday it acquired all the outstanding equity of Annovation Biopharma, a portfolio company of Atlas Venture. Financial terms weren’t announced. Cambridge, Massachusetts-based Annovation aims to create safer therapies for anesthesia and critical care.

114 Views

LTI picks up $20 mln Series A

Cambridge, Massachusetts-based Lysosomal Therapeutics Inc, which develops molecules to treat neurodegenerative diseases, has closed $20 million in Series A funding. The backers in this round included Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners.

122 Views

Button sews up $12 mln Series A

Redpoint Ventures has led a $12 million Series A funding round for Button, the latter announced in a post on its site. Other investors that participated in the round included Greycroft, DCM, Atlas Venture, VaynerRSE, Slow Ventures and NBA Commissioner Emeritus David Stern. Also, Redpoint’s Chris Moore has been appointed to Button’s board. Based in New York City, Button is a provider of customer acquisition and retention solutions for apps. To read the announcement, visit here.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget